Introduction
Granulocyte colony-stimulating factor (G-CSF) influences all stages of myelopoiesis, and is the cytokine critical for driving neutrophilic granulocyte differentiation. [1] [2] [3] [4] G-CSF induces quiescent stem cells to enter the cell cycle, stimulates myeloid progenitor cells to proliferate and differentiate, and most distinctively, promotes terminal neutrophilic maturation. Early studies with G-CSF explored its potential as a treatment for acute myelogenous leukemia (AML), with hopes that it would drive leukemic myeloid cells to terminally differentiate. 5 While a few cases of G-CSF-induced remission of AML have been described, [6] [7] [8] in the overwhelming majority of cases of AML, G-CSF-induced maturation is either incomplete or absent, while the proliferative response of these cells to G-CSF persists. 5, [8] [9] [10] [11] [12] [13] The basis for this aberrant maturational response of leukemic myeloid cells to G-CSF is unknown.
The diverse effects of G-CSF on normal myeloid cells are initiated through binding of G-CSF to its receptor (G-CSFR).
require the entire 183 amino acids of the cytoplasmic domain. 29, 31 In humans, there are five mRNA isoforms encoding the G-CSFR, classes I-V, which differ in their transmembrane and/or cytoplasmic domains as a result of alternative pre-mRNA splicing patterns of the single gene transcript. 15, [32] [33] [34] [35] The class I G-CSFR isoform, which is most homologous to the murine G-CSFR, contains the entire 183 amino acid cytoplasmic domain. The class II G-CSFR deletes the majority of the membrane spanning domain via alternative splicing and produces a soluble receptor; little is known about its function. The class III G-CSFR has an inframe 81 base pair insertion in the membrane proximal cytoplasmic domain which in studies of proliferative signaling appears to greatly diminish this signaling function. 29 The class IV isoform retains the membrane proximal sequence required for proliferative signaling functions, but replaces the carboxy-terminal region critical for maturational signaling with novel sequence, ablating its ability to drive neutrophilic differentiation. 28, 29, 31 The class V isoform removes even more of the carboxy-terminal region than does the class IV isoform, and replaces it with the same sequence as the class IV isoform, thus ablating both its mitogenic and maturational signaling capacities. 35 These differences in signaling function between the various G-CSF isoforms suggest the possibility that dysregulation of isoform expression could have significant effects on myelopoiesis and could contribute to the aberrant response of leukemia cells to G-CSF.
The goal of this study was to determine which of the five known G-CSF isoforms are expressed in normal myeloid progenitor cells, mature neutrophils, and AML cells, and then to detect any significant differences in G-CSFR isoform expression between these populations. Specifically, we wished to explore the possibility that increased expression of the differentiation-defective class IV and or class V G-CSFR isoforms occurs in myeloid leukemia. The results of this work indicate that a substantial proportion AML cells express increased levels of the class IV G-CSFR isoform compared to normal immature myeloid cells and circulating neutrophils.
Materials and methods

Cells
Normal neutrophils were obtained from healthy volunteers. Citrated fresh whole blood was depleted of erythrocytes by sedimentation in 1% dextran. The leukocyte fraction was washed with phosphate-buffered saline (PBS) and neutrophils isolated by centrifugation over a Ficoll gradient (Histopaque 1077; Sigma, St Louis, MO, USA). Remaining erythrocytes were lysed with sterile water and neutrophils counted and viability assessed by erythrosin-B dye exclusion. Neutrophils represented Ͼ95% of these cell preparations. 36 Human adult bone marrow (ABM) cells were obtained from vertebral bodies obtained at the time of organ harvesting from organ donors as described previously. 16 Mononuclear cells were isolated by centrifugation over a Ficoll gradient (Histopaque 1077; Sigma). Remaining erythrocytes were lysed with sterile water, the mononuclear cells were washed in PBS, and the CD34 + fraction was isolated using an immunoaffinity system (Ceprate; Cell Pro, Bothell, WA, USA). The CD34 + fraction was 1-3% of the total population, with purity of Ͼ87% by flow cytometric evaluation.
Leukemic cell samples from acute myelogenous leukemia patients were obtained from either heparinized bone marrow or peripheral blood which was collected during initial diagnostic evaluation and with informed consent of the patient. Samples were diluted 1:1 with sterile PBS and the leukemic cells isolated by centrifugation over a Ficoll gradient. The mononuclear fraction was recovered and remaining erythrocytes lysed with sterile water. Contaminating monocytes were removed by incubating cells in a sterile polystyrene dish (1 h, 37°C) and recovering the non-adherent leukemic cells. Leukemic cells make up Ͼ90% of the final population with viability typically Ͼ90% by erythrosin-B dye exclusion.
Leukemic cell lines DER, EM2, EM3, NB4, HL60, and THP-1 were maintained as described elsewhere. 36 33 This primer pair binds to an identical sequence in all five isoforms and amplifies a distinctly sized fragment from each isoform. The negative control used for PCR replaced cDNA with sterile filtered water and was amplified simultaneously with experimental reactions. Cloned G-CSFR cDNA sequence was used as template as a positive control for PCR. The thermal cycler (Perkin-Elmer Cetus) was programmed for denaturation at 95°C for 30 s, annealing at 55°C for 30 s, and elongation at 72°C for 1 min. Triplicate samples were removed from the thermal cycler after completion of a specific number of cycles. All controls were removed with the final experimental samples.
Analysis of PCR samples
Eight microliters of 50% glycerol/0.05% bromophenol blue were added to 10 l of PCR sample for loading onto 4% polyacrylamide gels. Samples were run at 250 V for 50 min then dried onto filter paper. The dried gels were then analyzed using a phosphorimager system (Molecular Dynamics, Sunnyvale, CA, USA) for quantitation of radioactive signal from individual bands. Total signal from a PCR product band was corrected for relative dCTP content of the fragment. Each cycle number was studied in triplicate and four consecutive cycles were examined for each sample unless indicated otherwise.
Cloning and sequencing of PCR fragments
The PCR products were electrophoretically separated on a 1% agarose gel, and each band captured onto nitrocellulose paper (Schleicher and Schuell, Keene, NH, USA). The PCR products were then cloned into pCR/SCRIPT (Stratagene, La Jolla, CA, USA) as directed by the manufacturer. Sequencing was performed using the Genesis 2000 system (Du Pont, Wilmington, DE, USA) at the University of Pittsburgh Cancer Institute DNA Sequencing Facility.
Statistical analysis
Ratios of class IV/class I G-CSFR expression for AML cell line samples, CD34
+ cells, AML patient samples, and circulating neutrophil samples were compared using the two-tailed Student's t-test.
Results
Detection of G-CSFR mRNA isoform expression by RT/PCR
Analysis of the G-CSFR mRNA isoforms was performed using RT/PCR. The previously described PCR primer pair HGR5/HGR3 allowed detection of all five known G-CSFR isoforms based on amplification of distinctly sized fragments ( Figure 1) . 33 Using these primers in preliminary RT/PCR studies of normal and leukemic myeloid cells, we detected only class I and class IV PCR products 33 (SM White; unpublished data). Before proceeding with a systematic examination of normal and leukemic cell samples, we optimized PCR conditions with regard to magnesium ion concentration and annealing temperature. A titration of magnesium ion concentration from 1 to 10 mM was performed at the annealing temperature of 55°C, which indicated that amplification appeared maximal at 1.5 mM, and then declined as magnesium ion concentration was increased (Figure 2a) . A range of annealing temperatures from 50°C to 65°C was examined, with the results demonstrating that above 60°C, amplification was significantly decreased, and below 55°C increased non-specific amplification was seen (Figure 2b ). Final PCR conditions therefore were set at an annealing temperature of 55°C and a magnesium ion concentration of 1.5 mM.
In addition to the fragments of 867 base pairs (class I) and 446 base pairs (class IV), an approximately 700 base pair fragment was observed which could have represented either the class II PCR fragment (780 base pairs) or a heteroduplex of class I and class IV PCR fragments (656 base pairs). To determine what this band was composed of, we cloned and sequenced the fragment. This yielded both class I and class IV sequence, but no class II sequence (data not shown). To confirm that the fragment represented a heteroduplex of class I and class IV PCR fragments, we performed a denaturation
Figure 2
Optimization of PCR using the primer pair HGR 5/HGR. (a) An ethidium bromide-stained 1% agarose gel indicating specific Mg++ concentrations examined for the amplification of class I and class IV G-CSFR cDNA sequence is shown. BPL is a 100 base pair DNA ladder. NEG is a negative control as outlined in Materials and methods. The millimolar concentration of Mg++ for each PCR sample is indicated above their respective lanes. The identity of each PCR fragment is indicated on the right. (b) An ethidium bromide-stained 1% agarose gel displaying a titration of annealing temperatures for amplification of class I and class IV G-CSFR cDNA sequence is shown. The annealing temperature used for each PCR sample is shown their respective lanes. (c) An ethidium bromide-stained 1% agarose gel which confirms the identity of the PCR fragment with a mobility of approximately 700 base pairs is shown. Class I indicates amplified class I cDNA sequence and class IV indicates amplified class IV cDNA sequence. PCR indicates co-amplification of both class I and class IV cDNA sequence. Annealed indicates the result of denaturing and re-annealing of separately amplified class I and class IV cDNA sequence. The identity of each PCR fragment is indicated to the right. and re-annealing experiment in which the class I and class IV cDNA sequences were amplified separately, then mixed and denatured at 100°C for 5 min, and allowed to reanneal. Agarose gel electrophoresis displayed a band which co-migrates precisely with the fragment produced from simultaneous class I and class IV sequence PCR amplification (Figure 2c) . Using the PCR conditions described above to amplify circulating neutrophil cDNA, three bands were observed with approximate sizes of 450, 700 and 875 base pairs corresponding with the predicted sizes for class IV (446 base pairs) and class I (867 base pairs) PCR fragments and a class I/class IV heteroduplex (Figure 3 ). PCR amplification of cDNA from the leukemic cell lines EM2 and EM3 also produced three bands of similar sizes (Figure 3) . No fragments of the predicted sizes for class II, III, or V PCR product were observed. Southern blot analysis of these PCR fragments (Figure 3 ) demonstrated crosshybridization with full-length class I G-CSFR cDNA further suggesting that these PCR fragments were derived from class I and class IV cDNA. To confirm the identity of the suspected class I and class IV PCR fragments, they were recovered separately by agarose gel electrophoresis, cloned into pCR/SCRIPT and sequenced. Each fragment contained the expected class I and class IV sequence (data not shown).
When the ethidium bromide staining of PCR products from neutrophils and the leukemic cell lines EM2 and EM3 were more closely examined, it appeared that in neutrophil samples the class I PCR fragment was more intense relative to the class IV fragment. However in the leukemic cell lines EM2 and EM3, the amount of the class IV product appeared increased relative to the class I product when compared to neutrophils (Figure 3) . In order to quantitate the actual ratio of class IV to class I mRNA, a quantitative PCR method was employed.
Assessment of relative G-CSFR mRNA isoform expression in normal and leukemic myeloid cells
To quantitate the relative expression of the G-CSFR isoforms in neutrophils and leukemic cells, 32 P-dCTP was incorporated into PCR products which were then electrophoretically separated on a 4% polyacrylamide gel. Dried gels were examined on a phosphorimager (Molecular Dynamics) which allows the radioactive signal from each band to be quantitated. Once this signal was adjusted for the dCTP content of each PCR fragment, the class IV/class I ratio was determined. Initial studies using G-CSFR class I and class IV cDNA sequence cloned into pCR/SCRIPT as template demonstrate an amplification efficiency of 0.85 for the class I PCR fragment and 0.85 for Figure 3 PCR amplification of myeloid leukemic cell line and circulating neutrophil cDNAs using the primer pair HGR 5/HGR 3. An ethidium bromide-stained 1% agarose gel and subsequent Southern blot are shown. BPL is a 100 base pair DNA ladder. NEG is a negative control as outlined in Materials and methods. POS is a positive control of amplified class I cDNA sequence. EM2 and EM3 are two myeloid leukemic cell lines from which cDNAs are obtained. PMN A and PMN B are normal circulating neutrophil cDNA samples from different subjects. The PCR fragment identities are indicated at the right. the class IV PCR fragment (P = 0.94) (Figure 4a ). This was confirmed using circulating neutrophil cDNA (Figure 4b) , with an amplification efficiency of 0.646 for the class I PCR fragment and of 0.630 for the class IV PCR fragment (P = 0.83). These results indicate that preferential amplification of the shorter class IV PCR fragment does not occur, thus allowing accurate comparison of the class I and class IV PCR products for any cycle during the linear phase of PCR amplification; this comparison then reflects the ratio of the original mRNA levels in the cell sample of interest. When this was done for circulating neutrophils the class IV/class I ratio was 0.037 ± 0.003, whereas the leukemic myeloid cell line EM2 demonstrated a ratio of 0.072 ± 0.006 (P = 0.007), indicating a significant difference in the relative expression of the G-CSFR isoforms between these two populations (Table 1, Figure 5 ).
Figure 4
Calculation of the PCR amplification efficiency for the class I and class IV PCR fragments from cloned class I and class IV cDNA in pCR/SCRIPT (a) and normal circulating neutrophil cDNA (b). The efficiency of PCR amplification for the class I and class IV G-CSFR PCR fragments was determined by performing Q-PCR analysis over four consecutive PCR cycles. The efficiency of amplification is equal to the slope of the curve of PCR product relative to cycle number. Once the corrected radioactive signal intensity was determined for each fragment at each cycle and plotted, the slope for each consecutive pair of cycles for each fragment was calculated. The average slope for each fragment was then calculated over the four cycle range and the statistical difference determined using the two-tailed Student's t-test. The relative G-CSFR isoform expression was measured in other AML cell lines, including AML-193, DER, EM3, HL60, KG-1, NB4 and THP-1. In all of these AML cell lines a significantly increased relative amount of class IV G-CSFR PCR product was observed when compared to circulating neutrophils, (Table 1, Figure 5 ), with the increases ranging from 1.8-to 9.5-fold (mean 3.1-fold). The cell line KG-1 displayed the greatest increase in class IV G-CSFR PCR product, with a class IV/class I ratio of 0.350. This ratio would have one class IV G-CSFR molecule for every two class I G-CSFR molecules.
To determine if the findings from the AML cell lines were an artifact of cell culture, leukemic cells from patients with AML were examined. Bone marrow or peripheral blood leukemic cells were collected during the initial diagnostic evaluation and Q-PCR examination performed. Results from six AML patient samples demonstrated that all six samples display increased levels of the class IV G-CSFR isoform when compared to normal neutrophils, with increases ranging from 1.8-to 4.1-fold (mean 2.6-fold) (Table 1, Figure 5 ).
The increased ratio of class IV to class I G-CSFR isoform expression observed in leukemic cells may be a reflection of their stage of maturational arrest during myeloid differentiation, or may be a manifestation of their leukemic phenotype. To determine if AML cells expressed an increased class IV/class I ratio relative to normal immature myeloid cells, the CD34 + fraction of adult bone marrow (ABM) cells was examined. Q-PCR examination of this CD34
+ cell population demonstrated a mean class IV/class I ratio of 0.065 ± 0.009 (Table 1, Figure 5 ). The relative G-CSFR class IV expression seen in three of eight AML cell lines and three of six AML patient samples is significantly greater than that seen in ABM CD34
+ cells (P Ͻ 0.05). These results indicate that in a substantial fraction of AML cell lines and AML patient samples, the abnormally increased relative levels of the differentiation- defective class IV G-CSFR isoform are related to the leukemic phenotype and not solely to their stage of maturation arrest.
Discussion
Using PCR methods, we examined which G-CSFR isoforms were expressed in normal and leukemic myeloid cells. Amplification of cDNA samples from circulating neutrophils and AML cell lines generated PCR products of the sizes expected for both the class I and the class IV G-CSFR isoforms. No PCR products corresponding to a class II, class III, or class V G-CSFR isoform fragment were observed. The identity of the PCR products was confirmed as being derived from class I and class IV G-CSFR sequence by cross-hybridization studies and by cloning and sequencing of the fragments. Once the equivalent PCR amplification efficiency was confirmed for the class I and class IV PCR fragments, quantitative PCR methods were used to determine the ratio of class IV/class I G-CSFR cDNA in circulating neutrophils and AML cell lines. All of the AML cell lines studied which expressed G-CSFR displayed significantly increased relative amounts of the differentiation-defective class IV G-CSFR isoform; the increase ranged from 1.7-to 9.5-fold when compared to neutrophil samples. In addition to the AML cell lines, all six AML patient samples demonstrated significantly increased relative levels of the differentiation-defective class IV G-CSFR isoform ranging from 1.8-to 4.1-fold, indicating that this finding is not a result of long-term cell culture. Three of eight AML cell lines and three of six AML patient samples displayed significantly increased relative levels of class IV G-CSFR when compared to normal immature myeloid cells. This is the first report of PCR examination of G-CSFR isoform expression in a series of normal and leukemic human myeloid cells. When the five human G-CSFR mRNA isoforms were originally cloned and identified, they were recovered from the histiocytic lymphoma cell line U937 (classes I and II), human placenta (classes I, III and IV), and circulating neutrophils (V). 11, 31, 35 We previously reported the isolation of 31 G-CSFR cDNA clones from the myeloblastic leukemia cell line HL60; 29 were class I, one was class III, and one was class IV. 33 In the present study, we identified expression of only class I and class IV G-CSFR isoforms in normal and leukemic myeloid cells; class III receptor was not detected in HL60 cells, or any other cell type examined. These findings suggest that the class III G-CSFR isoform is present at a low copy number per cell, as the previous isolation of only a single clone would also imply. On the other hand, our ability to detect the class IV receptor isoform in all cells examined suggests that this isoform is more abundant than our limited clonal analysis indicated.
Two hypotheses were initially considered to explain the disparity in relative expression of the class IV G-CSFR isoform in normal neutrophils and leukemic cells. One attributed this difference to the stage of maturational arrest of the leukemic cells, which implied that normal immature myeloid cells would also express relatively increased amounts of the class IV G-CSFR isoform. The other hypothesis portrayed the increased levels of class IV G-CSFR mRNA as part of the leukemic phenotype, and possibly contributing to the leukemic process, recognizing the strictly proliferative signaling function of the class IV isoform. To answer the question regarding relative G-CSFR isoform expression and stage of myeloid development, AML cell lines and AML patient samples were compared to ABM CD34 + cells, a population enriched for immature normal myeloid cells. Results demonstrated that three of eight AML cell lines and three of six AML patient samples expressed relative levels of G-CSFR class IV to class I isoforms which are significantly higher than in ABM CD34 + cells, indicating that the leukemic process contributes to the increased relative expression of the class IV G-CSFR isoform seen in a substantial subset of AML cell samples.
The implication of increased relative class IV G-CSFR expression in AML cells becomes evident when examined in the light of functional studies regarding G-CSFR signaling. Because the class IV G-CSFR isoform is only capable of transducing a proliferative signal and the signaling functions of its novel carboxy-terminal peptide sequence are yet unknown, it is conceivable that its over-expression could contribute to the imbalance favoring proliferation over maturation seen in AML. Since both class I and class IV G-CSFR isoforms are expressed in the leukemic cells, class IV G-CSFR may impede maturation in a dominant-negative manner through heterodimerization. If one assumes equivalency for the rate of mRNA translation and protein degradation, and equivalent kinetics of homo-vs heterodimerization, then G-CSFR class I and class IV homoor heterodimers will form following the rules of probability. With a ratio of class IV/class I of 0.037, as seen in neutrophils, class IV homodimers are 0.1% of all G-CSFR dimers, 7.1% are class IV/class I heterodimers, and 92.8% are class I homodimers. In normal CD34
+ ABM cells (class IV/class I = 0.065), this changes to 0.4, 12.2 and 87.4%, respectively. By comparison, in AML patient 5 (class IV/class I = 0.150) the odds become 2.25, 25.5 and 72.25%, respectively; representing a 2-to 3-fold increase in the percentage of heterodimers and a 5-to 20-fold increase in the percentage of class IV homodimers. Taking into account the fact that immature myeloid cells express fewer G-CSFR molecules at their surface, it is possible that a critical threshold of signaling for initiation of the G-CSFR-driven maturational programming is not achieved when less than three quarters of the available G-CSFR dimers are capable of providing this signal. [38] [39] [40] In addition, yet unknown signaling functions of the novel tyrosine motif in the carboxyterminus of the class IV isoform may also contribute an antimaturational signal by either the homodimer or heterodimer. Studies are ongoing which examine the signaling events initiated by this tyrosine motif and the relative stability of the class I and class IV G-CSFR proteins.
The possibility that a dominant-negative effect on maturational signaling could result from heterodimers containing the differentiation-defective class IV isoform is supported by recent studies of two patients with Kostmann's syndrome (severe congenital neutropenia) who developed AML. 41 Point mutations in one allele of the G-CSFR gene in each patient resulted in premature stop codons in the G-CSFR mRNA transcript. The resultant truncations produce mutant receptor isoforms which lack the distal 83 or 97 amino acids of the class I isoform which are required for maturational signaling; the same amino acids which the class IV isoform replaces with novel carboxy-terminal peptide sequence. These mutant isoforms were also found to be differentiation-defective in their signaling function, as is the class IV isoform. Studies examining the co-expression of these mutant isoforms with the fulllength G-CSFR in the murine myeloblastic cell line 32D suggest that these mutant isoforms are capable of exerting a dominant-negative effect on class I G-CSFR maturational signaling as evidenced by blocking of G-CSF-mediated differentiation. Truncated mutant G-CSFR alleles have been identified in, at most, 29% of Kostmann's syndrome patients, and less than 3% of AML patients thus far reported. 35, 41, 42 The results presented here demonstrate increased relative levels of the naturally occurring class IV isoform in three of seven AML patients, suggesting that this abnormality may be a much more common event in AML.
Since the class IV isoform is derived by alternative splicing of the G-CSFR pre-mRNA transcript, RNA processing may be aberrantly regulated in leukemic cells. Other examples of aberrant regulation of pre-mRNA alternative splicing in myeloid leukemias have been presented in the literature. One example is the generation of blast crisis in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph1 + CML), where after entering blast crisis, the chimeric BCR/ABL transcript is noted to use the BCR exon b3 preferentially over exon b2 in a number of cases. 43, 44 A second example seen in both AML and acute lymphoid leukemias (ALL), is the expression of an alternatively spliced form of the Src-related protein tyrosine kinase, Lck. 43 Normally, type IIA is highly expressed in T lymphocytes, with B lymphocytes expressing type IB, but at very low levels. However, in ALL and AML subtypes M1 and M2, Lck-type IB is highly expressed. The IB pattern occurs due to recognition of a cryptic 5′ splice donor site in the mRNA transcript, similar to how G-CSFR class IV isoform is derived. When patients with AML M1 or M2 are treated and in remission, the normal expression pattern of Lck returns. A study of AML patient samples has also identified increased expression of a splice variant of the transcription factor AML1 that is associated with the leukemic phenotype. 44 This splice variant (AML1a) is also produced by recognition of cryptic splice donor and acceptor sites in the carboxy-terminal region of the transcript, similar to how the class IV G-CSFR isoform is derived. This results in a DNA binding protein without the transcriptionally active domain and presumably acts via a dominant-negative mechanism to inhibit transcription. These examples all occur through similar mechanisms of alternative pre-mRNA splicing as the class IV G-CSFR isoform. This suggests an aberrant expression of some factor directly involved with regulating alternative splicing pattern recognition in leukemic myeloid cells.
The response of AML cells to G-CSF exposure is heterogeneous, with some exhibiting only proliferation, others showing evidence of abnormal granulocytic maturation, and in rare cases, complete terminal neutrophilic differentiation. [5] [6] [7] [8] [9] [10] [11] 13 Our results raise the possibility that this heterogeneity in response may be explained on the basis of relative G-CSFR isoform expression. Leukemic cells which proliferate but fail to terminally differentiate in response to G-CSF may express abnormally high levels or fail to down-regulate the expression of the differentiation-defective class IV isoform, while the leukemic cells of patients who respond to G-CSF by entering into remission may express and regulate levels of the class IV isoform similar to normal myeloid cells. We are currently exploring the correlation between the response of leukemic cells to G-CSF and their G-CSFR isoform expression to determine if this hypothesis is correct.
